Tests burning nerve endings in the heart to treat recurrent atrial fibrillation
Tests ablation of heart nerve endings in adults whose atrial fibrillation returned after treatment.
Key facts
- Who runs it
- Imperial College London
- Where
- London, United KingdomSee the site
- Trial code
- Registry title
- The Role of Right Atrial Ectopy Triggering Ganglionated Plexuses in AF
- Status
- Recruiting
- People taking part
- 116 people, planned
- Started
- 21 Feb 2023
- Expected to end
- 2 Dec 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Right Atrial ganglionated plexus ablation
- Holter Monitor
- Pulmonary vein isolation
- Right cavo-tricuspid and left roof linear ablation
- Personal ECG recordings
- Quality of life questionnaire
- Record updated
- 28 September 2023
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 85 with symptomatic paroxysmal atrial fibrillation who can have catheter ablation.
- Age
- 18 to 85 years
- Sex
- Men and women can join.
- Disease stage
- Symptomatic paroxysmal atrial fibrillation.
Main reasons for not taking part
- Any form of cardiomyopathy
- Moderate or worse valvular disease
- Moderate to severe heart failure (NYHA Class III-IV)
- Uncontrolled diabetes
- Pregnancy, or women who could become pregnant and do not use a highly effective method of contraception
The registry criteria, word for word
Show all 21 criteriaShow less
Who can take part
- Males or females from 18 to 85yrs old
- Symptomatic paroxysmal atrial fibrillation
- Suitable candidate for catheter ablation
- Signed informed consent
Who cannot take part
- Valvular disease that is grade moderate or greater
- Severe cerebrovascular disease
- Active gastrointestinal bleeding
- Active infection or fever
- Allergy to contrast
- Moderate to severe heart failure and/or NYHA Class III-IV
- Bleeding or clotting disorders or inability to receive heparin
- Malignancy needing therapy
- Serum Creatinine >200umol/L/ on dialysis/ at risk of dialysis
- Uncontrolled diabetes (HbA1c ≥73mmol/mol or HbA1c ≤64mmol/mol and Fasting Blood Glucose ≥9.2mmol/L)
- Contraindication to catheter ablation
- Contraindication for general anaesthetic
- Presence of a left ventricular thrombus
- Any form of cardiomyopathy
- Life expectancy shorter than the duration of the trial
- Pregnancy or women of childbearing potential not using a highly effective method of contraception
- Unable to give informed consent
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 85 years old?
Where in United Kingdom
- Hammersmith HospitalLondon, United KingdomContact: Jamie Kay, MBBS, BMedSciTaking people
About the trial
What the trial wants to find out
Atrial fibrillation (AF) is the most common rhythm disturbance of the heart. It can affect people of any age but usually happens as we get older. It can cause palpitations, breathlessness, lethargy, and fainting attacks. It is also associated with an increased risk of strokes.
Read full original descriptionShow less
The best treatment for it at the moment involves burning or freezing (ablation) the heart muscle in a part of the heart called the left atrium. The ablation injures the heart muscle around the so-called pulmonary veins and the procedure is called a 'pulmonary vein isolation'. This procedure work in about 60% of people.
The study team have found that there are nerve endings in the heart that also cause AF and have shown that ablating these nerve endings also prevents AF. These Nerve endings are known as ganglionated plexuses (GPs).
The study team would now like to perform a trial in people who still have AF after the usual pulmonary vein procedure. The study team hope that ablating the nerve endings that cause AF (GPs), we will stop their AF coming back. The study team will compare this procedure to the normal approach of doing the pulmonary vein isolation again
The 2 groups in the trial
- InterventionTreatment being tested
Right atrial GP ablation in addition to pulmonary vein isolation
Treatment: Right Atrial ganglionated plexus ablation, Holter Monitor, Pulmonary vein isolation, Personal ECG recordings, and Quality of life questionnaire
- ControlExisting treatment, for comparison
PVI alone with no GP mapping or ablation
Treatment: Holter Monitor, Pulmonary vein isolation, Right cavo-tricuspid and left roof linear ablation, Personal ECG recordings, and Quality of life questionnaire
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Understanding the Role of Right Atrial Ectopy-triggering Ganglionated Plexuses in Atrial Fibrillation
- Plain-language title
- Tests burning nerve endings in the heart to treat recurrent atrial fibrillationGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT05539040, who can take part
- Record updated
- 28 September 2023